Oral glucose tolerance tests in treated patients with schizophrenia. Data to support an adaptation of the proposed guidelines for monitoring of patients on second generation antipsychotics?

European Psychiatry

Volumn 21, Issue 4, 2006, Pages 224-226

  De Hert, Marc ^a   Van Eyck, Dominique ^a   Hanssens, Linda ^b   Peuskens, Hendrik ^a   Thys, Erik ^a   Wampers, Martien ^a   Scheen, Andre ^c   Peuskens, Jozef ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Antipsychotics; Diabetes; Metabolic syndrome; Schizophrenia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; BELGIUM; CLINICAL FEATURE; CONTROLLED STUDY; DATA ANALYSIS; DISEASE CLASSIFICATION; ELECTROCARDIOGRAM; EVALUATION; FEMALE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PATIENT MONITORING; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BELGIUM; ELECTROCARDIOGRAPHY; FEMALE; GLUCOSE METABOLISM DISORDERS; GLUCOSE TOLERANCE TEST; HUMANS; MALE; MASS SCREENING; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA;

EID: 33745275796     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2005.05.011     Document Type: Article

References (22)

1. American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27 2 (2004) 596-601
2. Caro J.J., Ward A., Levinton C., and Robinson K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J. Clin. Psychiatry 63 12 (2002) 1135-1139
3. Citrome L.L., and Jaffe A.B. Relationship of atypical antipsychotics with development of diabetes mellitus. Ann. Pharmacother. 37 (2003) 1849-1857
4. De Hert M., Hanssens L., de Patoul A., and Peuskens J. Pharmacological treatment of ambulatory schizophrenic patients in Belgium. Schiz. Res. 67 (2004) (Abstracts Winter Workshop on Schizophrenia)
5. De Nayer A., DeHert M., Scheen A., et al. Belgian consensus on metabolic problems associated with second generation antipsychotics. Int. J. Psychiatry Clin. Pract. 9 (2005) 130-137
6. Ebenbilcher C., Laimer M., Eder U., Mangwerth B., Weiss E., Hofer A., et al. Olanzapine induced insulin resistance: results from a prospective study. J. Clin. Psychiatry 64 12 (2003) 1436-1439
7. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J. Clin. Psychiatry 57 (2002) 12-15
8. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26, Suppl 1 (2003) S5-S20
9. Expert Group. Schizophrenia and diabetes 2003. Expert consensus meeting, Dublin 3-4 October 2003: consensus summary. Brit. J. Psy. 184 (2004) S112-S114
10. Expert Panel on Detection. Evaluation and treatment of blood cholesterol in adults. Extensive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA 285 (2001) 2486-2497
11. Gianfrancesco F., White R., Wang R.H., and Nasrallah H.A. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J. Clin. Psychopharmacol. 23 4 (2003) 328-335
12. Hedenmalm K., Hagg S., Stahl M., Mortimer O., and Spigset O. Glucose intolerance with atypical antipsychotics. Drug Saf. 25 15 (2002) 1107-1116
13. Henderson D.C. Atypical antipsychotic-induced diabetes mellitus, how strong is the evidence. CNS Drugs 16 (2002) 77-89
14. Howes O.D., Bhatnagar A., Gaugran F.P., Amiel S.A., Murray R.M., and Pilowsky L.S. A prospective study of impairement in glucose control caused by clozapine without changes in insulin resistance. Am. J. Psychiatry 161 (2004) 361-363
15. Lean M.E., and Pajonk F.G. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care 26 5 (2003) 1597-1605
16. Lorenzo C., Okoloise M., Williams K., Stern M.P., and Haffner S.M. The metabolic syndrome as predictor of Type-2 diabetes. Diabetes Care 26 (2003) 3153-3159
17. Lindenmayer J.P., Czobor P., Volavka J., Citrome L.L., Sheitman B., McEvoy J.P., et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical and atypical antipsychotics. Am. J. Psychiatry 160 (2003) 290-296
18. Melkersson K., and Dahl M.-L. Adverse metabolic effects associated with atypical antipsychotics. Drugs (2004) 701-723
19. Newcomer J.W., Haupt D.W., Fucetola R., Melson A.K., Schweiger J.A., Cooper B.P., et al. Abnormalities in glucose regulation during antipsychotic treatment. Arch. Gen. Psychiatry 59 (2002) 337-345
20. Sernyak M.J., Leslie D.L., Alarcon R.D., Losonczy M.F., and Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am. J. Psychiatry 159 4 (2002) 561-566
21. Stern M.P., Williams K., and Haffner S.M. Identification of persons at high risk for Type-2 diabetes: do we need the oral glucose tolerance test. Ann. Intern. Med. 136 (2002) 575-581
22. Wampers M., De Hert M., Van Eyck D., and Peuskens J. Somatic medication in hospitalised schizophrenic patients in Belgium. Schiz. Res. 67 (2004) (Abstracts Winter Workshop on Schizophrenia)